The Future of Central Nervous System Diseases Therapeutics

Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Product Code GBI00002
Publication Date December 2009
Publisher GBI Research
Product Type Report
Pages 198
ISBN Number not applicable
Change currency
PDF £2,215.00 €2,667 $3,502 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

The Future of Central Nervous System Diseases Therapeutics

Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

GBI Research, the leading business intelligence provider, has released its latest research "The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global CNS diseases therapeutics market. The report analyzes the markets for CNS disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

  • Annualized market data for the CNS diseases therapeutics market from 2000 to 2008, forecast forward to 2015
  • Analysis of the leading therapeutic segments including Alzheimer's disease, Parkinson's disease, Schizophrenia and Bipolar Disorder, Epilepsy, Major depressive disorder (MDD), anxiety and panic disorder, Attention Deficit Hyperactivity Disorder (ADHD) and Insomnia.
  • Analysis of the CNS diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
  • Market characterization of the CNS diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of pipeline molecules in various phases of drug development
  • Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Lundbeck A/S, AstraZeneca, Merck & Co, Pfizer Inc, UCB S.A., Bristol-Myers Squibb and Eli Lilly
  • Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global CNS diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

  • Align product portfolio to the markets with high growth potential
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
  • Develop key strategic initiatives by understanding key focus areas of leading companies
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Global CNS Therapeutics Market : Introduction
    • 2.1 Disease Overview
    • 2.2 GBI Research Report Guidance
  • 3 Global CNS Therapeutics Market: Market Characterization
    • 3.1 Market Overview
    • 3.2 Market Forecasts
    • 3.3 Branded Versus Generics
    • 3.4 Market Share by Disease Sectors
    • 3.5 Average Cost of Therapy
    • 3.6 Volume
    • 3.7 Usage Patterns
      • 3.7.1 Diseased Population
      • 3.7.2 Treatment Seeking Population
      • 3.7.3 Diagnosis Population
      • 3.7.4 Prescription Population
      • 3.7.5 Therapeutic Usage Patterns
    • 3.8 Geographical Distribution
    • 3.9 Market Drivers and Restraints
      • 3.9.1 Market Drivers
      • 3.9.2 Market Restraints
    • 3.10 Unmet Needs
      • 3.10.1 Alzheimer's Disease
      • 3.10.2 Parkinson's Disease
      • 3.10.3 Schizophrenia and bipolar Disorder
      • 3.10.4 Depression
      • 3.10.5 Insomnia
    • 3.11 Key Market Trends
      • 3.11.1 Increase in Disease Incidence and Prevalence Rates
      • 3.11.2 Product Pipeline
      • 3.11.3 Advertising and Commercialization
      • 3.11.4 Regulatory trends - Current Reimbursement Scenario
  • 4 Global Alzheimer's Disease Therapeutics Market
    • 4.1 Market Overview
    • 4.2 Market Forecasts
    • 4.3 Average Cost of Therapy
    • 4.4 Volume
    • 4.5 Usage Patterns
      • 4.5.1 Diseased Population
      • 4.5.2 Treatment Seeking Population
      • 4.5.3 Diagnosis Population
      • 4.5.4 Prescription Population
      • 4.5.5 Therapeutic Usage Patterns
    • 4.6 Product Analysis
      • 4.6.1 Aricept
      • 4.6.2 Exelon and Exelon Patch
      • 4.6.3 Ebixa (Namenda)
      • 4.6.4 Razadyne and Reminyl
    • 4.7 Drug Pipeline Analysis
  • 5 Global Parkinson's Disease Therapeutics Market
    • 5.1 Market Overview
    • 5.2 Market Forecasts
    • 5.3 Average Cost of Therapy
    • 5.4 Volume
    • 5.5 Usage Patterns
      • 5.5.1 Diseased Population
      • 5.5.2 Treatment Seeking Population
      • 5.5.3 Diagnosis Population
      • 5.5.4 Prescription Population
      • 5.5.5 Therapeutic Usage Patterns
    • 5.6 Product Analysis
      • 5.6.1 Azilect
      • 5.6.2 Stalevo/Comtan
      • 5.6.3 Madopar
      • 5.6.4 Neupro
      • 5.6.5 Requip/Requip XL
      • 5.6.6 Sifrol/Mirapex
      • 5.6.7 Sinemet
    • 5.7 Drug Pipeline Analysis
  • 6 Global Schizophrenia and Bipolar Disorder Therapeutics Market
    • 6.1 Market Overview
    • 6.2 Market Forecasts
    • 6.3 Average Cost of Therapy
    • 6.4 Volume
    • 6.5 Usage Patterns
      • 6.5.1 Diseased Population
      • 6.5.2 Treatment Seeking Population
      • 6.5.3 Diagnosis Population
      • 6.5.4 Prescription Population
      • 6.5.5 Therapeutic Usage Patterns
    • 6.6 Product Analysis
      • 6.6.1 Abilify
      • 6.6.2 Clozaril
      • 6.6.3 Geodon/Zeldox
      • 6.6.4 Invega
      • 6.6.5 Risperdal/Risperdal Consta
      • 6.6.6 Serdolect
      • 6.6.7 Seroquel
      • 6.6.8 Zyprexa
    • 6.7 Drug Pipeline Analysis
  • 7 Global Epilepsy Therapeutics Market
    • 7.1 Market Overview
    • 7.2 Market Forecasts
    • 7.3 Average Cost of Therapy
    • 7.4 Volume
    • 7.5 Usage Patterns
      • 7.5.1 Diseased Population
      • 7.5.2 Treatment Seeking Population
      • 7.5.3 Diagnosis Population
      • 7.5.4 Prescription Population
      • 7.5.5 Therapeutic Usage Patterns
    • 7.6 Product Analysis
      • 7.6.1 Depakine
      • 7.6.2 Keppra/Keppra XR and Vimpat
      • 7.6.3 Lamictal
      • 7.6.4 Lyrica
      • 7.6.5 Neurontin
      • 7.6.6 Tegretol
      • 7.6.7 Trileptal
      • 7.6.8 Topamax
      • 7.6.9 Vimpat
    • 7.7 Drug Pipeline Analysis
  • 8 Global MDD, Anxiety and Panic Disorder Therapeutics Market
    • 8.1 Market Overview
    • 8.2 Market Forecasts
    • 8.3 Average Cost of Therapy
    • 8.4 Volume
    • 8.5 Usage Patterns
      • 8.5.1 Diseased Population
      • 8.5.2 Treatment Seeking Population
      • 8.5.3 Diagnosis Population
      • 8.5.4 Prescription Population
      • 8.5.5 Therapeutic Usage Patterns
    • 8.6 Product Analysis
      • 8.6.1 Celexa
      • 8.6.2 Cipralex
      • 8.6.3 Cymbalta
      • 8.6.4 Effexor
      • 8.6.5 Lexapro
      • 8.6.6 Pristiq
      • 8.6.7 Seroxat/Paxil
      • 8.6.8 Wellbutrin/Wellbutrin XL
      • 8.6.9 Xanax
      • 8.6.10 Zoloft
    • 8.7 Drug Pipeline Analysis
  • 9 Global ADHD Therapeutics Market
    • 9.1 Market Overview
    • 9.2 Market Forecasts
    • 9.3 Average Cost of Therapy
    • 9.4 Volume
    • 9.5 Usage Patterns
      • 9.5.1 Diseased Population
      • 9.5.2 Treatment Seeking Population
      • 9.5.3 Diagnosis Population
      • 9.5.4 Prescription Population
      • 9.5.5 Therapeutic Usage Patterns
    • 9.6 Product Analysis
      • 9.6.1 Adderall/Adderall XR
      • 9.6.2 Concerta
      • 9.6.3 Daytrana
      • 9.6.4 Focalin/Retalin
      • 9.6.5 Strattera
      • 9.6.6 Vyvanse
    • 9.7 Drug Pipeline Analysis
  • 10 Global Insomnia Therapeutics Market
    • 10.1 Market Overview
    • 10.2 Market Forecasts
    • 10.3 Average Cost of Therapy
    • 10.4 Volume
    • 10.5 Usage Patterns
      • 10.5.1 Diseased Population
      • 10.5.2 Treatment Seeking Population
      • 10.5.3 Diagnosis Population
      • 10.5.4 Prescription Population
      • 10.5.5 Therapeutic Usage Patterns
    • 10.6 Product Analysis
      • 10.6.1 Halcion
      • 10.6.2 Lunesta
      • 10.6.3 Rozerem
      • 10.6.4 Ambien/Stilnox/Ambien CR
      • 10.6.5 Sonata
    • 10.7 Drug Pipeline Analysis
  • 11 Global CNS Therapeutics Market: The US Market
    • 11.1 Market Overview
    • 11.2 Market Forecasts
    • 11.3 Average Cost of Therapy
    • 11.4 Volume
    • 11.5 Usage Patterns
      • 11.5.1 Diseased Population
      • 11.5.2 Treatment Seeking Population
      • 11.5.3 Diagnosis Population
      • 11.5.4 Prescription Population
      • 11.5.5 Therapeutic Usage Patterns
  • 12 Global CNS Therapeutics Market: The European Market
    • 12.1 Market Overview
    • 12.2 Market Forecasts
    • 12.3 Average Cost of Therapy
    • 12.4 Volume
    • 12.5 Usage Patterns
      • 12.5.1 Diseased Population
      • 12.5.2 Treatment Seeking Population
      • 12.5.3 Diagnosis Population
      • 12.5.4 Prescription Population
      • 12.5.5 Therapeutic Usage Patterns
  • 13 Global CNS Therapeutics Market: The Japanese Market
    • 13.1 Market Overview
    • 13.2 Market Forecasts
    • 13.3 Average Cost of Therapy
    • 13.4 Volume
    • 13.5 Usage Patterns
      • 13.5.1 Diseased Population
      • 13.5.2 Treatment Seeking Population
      • 13.5.3 Diagnosis Population
      • 13.5.4 Prescription Population
      • 13.5.5 Therapeutic Usage Patterns
  • 14 Global CNS Therapeutics Market: Competitive Landscape
    • 14.1 Overview
    • 14.2 Market Share Analysis
    • 14.3 Competitive Profiling
      • 14.3.1 AstraZeneca
      • 14.3.2 Boehringer Ingelheim
      • 14.3.3 Bristol-Myers Squibb
      • 14.3.4 Eli Lilly
      • 14.3.5 GlaxoSmithKline (GSK)
      • 14.3.6 Johnson & Johnson
      • 14.3.7 H. Lundbeck A/S
      • 14.3.8 Novartis
      • 14.3.9 Pfizer
      • 14.3.10 Sanofi Aventis
      • 14.3.11 Shire Pharmaceuticals
      • 14.3.12 UCB Pharma
      • 14.3.13 Wyeth
  • 15 Global CNS Therapeutics Market: Strategic Consolidations
    • 15.1 Mergers and Acquisitions
      • 15.1.1 Overview
    • 15.2 Licensing Agreements
      • 15.2.1 Preclinical
      • 15.2.2 Phase I
      • 15.2.3 Phase II
      • 15.2.4 Phase III
      • 15.2.5 Approved
  • 16 Global CNS Therapeutics Market : Appendix
    • 16.1 Market Definitions
    • 16.2 Abbreviations
    • 16.3 Research Methodology
    • 16.4 Coverage
    • 16.5 Secondary Research
    • 16.6 Primary Research
    • 16.7 Models
    • 16.8 Forecasts
      • 16.8.1 Epidemiology-based Forecasting
    • 16.9 Expert Panel Validation
    • 16.10 Contact Us
    • 16.11 Disclaimer
  • 1.1 List of Tables
    • Table 1: CNS Therapeutics Market, Global, Revenues ($m), 2000-2008
    • Table 2: CNS Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015
    • Table 3: CNS Therapeutics Market, Global, Revenue Segmentation ($m), 2000-2008
    • Table 4: CNS Therapeutics Market, Global, Revenue Segmentation ($m), 2008-2015
    • Table 5: CNS Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008
    • Table 6: CNS Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015
    • Table 7: CNS Therapeutics Market, Global, Historical Figures for Volume (000), 2000-2008
    • Table 8: CNS Therapeutics Market, Global, Forecasts for Volume, 2008-2015
    • Table 9: CNS Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008
    • Table 10: CNS Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
    • Table 11: CNS Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table 12: CNS Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 13: CNS Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008
    • Table 14: CNS Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
    • Table 15: CNS Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008
    • Table 16: CNS Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
    • Table 17: CNS Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008
    • Table 18: CNS Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 19: CNS Therapeutics Market, Global, Market Drivers, 2008
    • Table 20: CNS Therapeutics Market, Global, Market Restraints, 2008
    • Table 21: CNS Therapeutics Market, Global, Major Drug Patent Expirations, 2008-2015
    • Table 22: CNS Therapeutics Market, Global, Reimbursement Policies of Various
    • Table 23: Alzheimer's Disease Therapeutics Market, Historical Revenue ($m), 2000-2008
    • Table 24: Alzheimer's Disease Therapeutics Market, Revenue Forecasts ($m), 2008-2015
    • Table 25: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008
    • Table 26: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015
    • Table 27: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Volume, 2000-2008
    • Table 28: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Volume, 2008-2015
    • Table 29: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008
    • Table 30: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
    • Table 31: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table 32: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 33: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008
    • Table 34: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
    • Table 35: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008
    • Table 36: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
    • Table 37: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008
    • Table 38: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 39: Alzheimer's Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
    • Table 40: Alzheimer's Disease Therapeutics Market, Global, Clinical Trials Pipeline, 2008
    • Table 41: Parkinson's Disease Therapeutics Market, Global, Historical Revenues ($m), 2000-2008
    • Table 42: Parkinson's Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015
    • Table 43: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008
    • Table 44: Parkinson's Disease Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015
    • Table 45: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Volume, 2000-2008
    • Table 46: Parkinson's Disease Therapeutics Market, Global, Forecasts for Volume, 2008-2015
    • Table 47: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008
    • Table 48: Parkinson's Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
    • Table 49: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table 50: Parkinson's Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 51: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008
    • Table 52: Parkinson's Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
    • Table 53: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008
    • Table 54: Parkinson's Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
    • Table 55: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008
    • Table 56: Parkinson's Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 57: Parkinson's Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
    • Table 58: Parkinson's Disease Therapeutics Market, Global, Clinical Trials Pipeline, 2008
    • Table 59: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Revenues ($m), 2000-2008
    • Table 60: Schizophrenia and Bipolar Disorder Therapeutics Market, Global,, Revenue Forecasts ($m), 2008-2015
    • Table 61: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008
    • Table 62: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015
    • Table 63: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Volume, 2000-2008
    • Table 64: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Volume, 2008-2015
    • Table 65: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008
    • Table 66: Schizophrenia and Bipolar Disorder Therapeutics Market, Forecasts for Diseased Population, 2008-2015
    • Table 67: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table 68: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 69: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008
    • Table 70: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
    • Table 71: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008
    • Table 72: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
    • Table 73: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008
    • Table 74: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 75: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
    • Table 76: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008
    • Table 77: Epilepsy Therapeutics Market, Global, Historical Revenues ($m), 2000-2008
    • Table 78: Epilepsy Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015
    • Table 79: Epilepsy Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008
    • Table 80: Epilepsy Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015
    • Table 81: Epilepsy Therapeutics Market, Global, Historical Figures for Volume, 2000-2008
    • Table 82: Epilepsy Therapeutics Market, Global, Forecasts for Volume, 2008-2015
    • Table 83: Epilepsy Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008
    • Table 84: Epilepsy Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
    • Table 85: Epilepsy Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table 86: Epilepsy Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 87: Epilepsy Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008
    • Table 88: Epilepsy Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
    • Table 89: Epilepsy Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008
    • Table 90: Epilepsy Therapeutics Market, Forecasts for Prescription Population, 2008-2015
    • Table 91: Epilepsy Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patters, 2000-2008
    • Table 92: Epilepsy Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 93: Epilepsy Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
    • Table 94: Epilepsy Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008
    • Table 95: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Revenues ($m), 2000-2008
    • Table 96: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015
    • Table 97: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008
    • Table 98: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015
    • Table 99: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Volume, 2000-2008
    • Table 100: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Volume, 2008-2015
    • Table 101: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008
    • Table 102: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
    • Table 103: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historic Figures for Treatment Seeking Population, 2000-2008
    • Table 104: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 105: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008
    • Table 106: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
    • Table 107: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008
    • Table 108: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
    • Table 109: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008
    • Table 110: MDD, Anxiety Panic Disorder Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 111: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
    • Table 112: Global MDD, Panic and Anxiety Disorder Therapeutics Market, Clinical Trials Drug Portfolio, 2008
    • Table 113: Global ADHD Therapeutics Market, Historical Revenues ($m), 2000-2008
    • Table 114: Global ADHD Therapeutics Market, Revenues Forecasts ($million), 2008-2015
    • Table 115: ADHD Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008
    • Table 116: ADHD Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015
    • Table 117: Global ADHD Therapeutics Market, Historical Figures for Volume, 2000-2008
    • Table 118: Global ADHD Therapeutics Market, Forecasts for Volume, 2008-2015
    • Table 119: Global ADHD Therapeutics Market, Historical Figures for Diseased Population, 2000-2008
    • Table 120: Global ADHD Therapeutics Market, Forecasts for Diseased Population, 2008-2015
    • Table 121: Global ADHD Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table 122: Global ADHD Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 123: Global ADHD Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008
    • Table 124: Global ADHD Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015
    • Table 125: Global ADHD Therapeutics Market, Historical Figures for Prescription Population, 2000-2008
    • Table 126: Global ADHD Therapeutics Market, Forecasts for Prescription Population, 2008-2015
    • Table 127: Global ADHD Therapeutics Market, Historical Figures for Therapeutic Usage Patterns, 2000-2008
    • Table 128: Global ADHD Therapeutics Market, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 129: Global ADHD Therapeutics Market, Major Manufacturers and Drugs, 2008
    • Table 130: Global Insomnia Therapeutics Market, Historical Revenues ($m), 2000-2008
    • Table 131: Global Insomnia Therapeutics Market, Revenue Forecasts ($m), 2008-2015
    • Table 132:Global Insomnia Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008
    • Table 133: Global Insomnia Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015
    • Table 134: Insomnia Therapeutics Market, Historical Figures for Volume, 2000-2008
    • Table 135: Insomnia Therapeutics Market, Forecasts for Volume, 2008-2015
    • Table 136: Global Insomnia Therapeutics Market, Historical Figures for Diseased Population, 2000-2008
    • Table 137: Global Insomnia Therapeutics Market, Forecasts for Diseased Population, 2008-2015
    • Table 138: Global Insomnia Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table 139: Insomnia Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 140: Global Insomnia Therapeutics Market,Historical Figures for Diagnosis Population, 2000-2008
    • Table 141: Global Insomnia Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015
    • Table 142: Global Insomnia Therapeutics Market, Historical Figures for Prescription Population, 2000-2008
    • Table 143: Global Insomnia Therapeutics Market, Forecasts for Prescription Population, 2008-2015
    • Table 144: Global Insomnia Therapeutics Market, Historical Figures for Therapeutic Usage Patterns, 2000-2008
    • Table 145: Global Insomnia Therapeutics Market, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 146: Global Insomnia Therapeutics Market, Major Manufacturers and Drugs, 2008
    • Table 147: Insomnia Therapeutics Market, Clinical Trials Pipeline, 2008
    • Table 148: CNS Therapeutics Market, US, Historical Revenues ($m), 2000-2008
    • Table 149: CNS Therapeutics Market, US, Revenue Forecasts ($m), 2008-2015
    • Table 150: CNS Therapeutics Market, US, Historical Figures for the Average Cost of Therapy ($), 2000-2008
    • Table 151: CNS Therapeutics Market, US, Forecasts for the Average Cost of Therapy ($), 2008-2015
    • Table 152: CNS Therapeutics Market, US, Historical Figures for Volume, 2000-2008
    • Table 153: CNS Therapeutics Market, US, Forecasts for Volume, 2008-2015
    • Table 154: CNS Therapeutics Market, US, Historical Figures for Diseased Population,2000-2008
    • Table 155: CNS Therapeutics Market, US, Forecasts for Diseased Population, 2008-2015
    • Table 156: CNS Therapeutics Market, US, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table 157: CNS Therapeutics Market, US, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 158: CNS Therapeutics Market, US, Historical Figures for Diagnosis Population,2000-2008
    • Table 159: CNS Therapeutics Market, US, Forecasts for Diagnosis Population, 2008-2015
    • Table 160: CNS Therapeutics Market, US, Historical Figures for Prescription Population,2000-2008
    • Table 161:CNS Therapeutics Market, US, Forecasts for Prescription Population, 2008-2015
    • Table 162:CNS Therapeutics Market, US, Historical Figures for Usage Patterns, 2000-2008
    • Table163: CNS Therapeutics Market, US, Forecasts for Usage Patterns, 2008-2015
    • Table 164: CNS Therapeutics Market, Europe, Historical Revenues ($m), 2000-2008
    • Table 165: CNS Therapeutics Market, Europe, Revenue Forecasts ($m), 2008-2015
    • Table 166: CNS Therapeutics Market, Europe, Historical Figures for Average Cost of Treatment, 2000-2008
    • Table 167: CNS Therapeutics Market, Europe, Forecasts for Average Cost of Treatment, 2008-2015
    • Table 168: CNS Therapeutics Market, Europe, Historical Figures for Volume, 2000-2008
    • Table 169: CNS Therapeutics Market, Europe, Forecasts for Volume, 2008-2015
    • Table 170: CNS Therapeutics Market, Europe, Historical Figures for Diseased Population,2000-2008
    • Table 171: CNS Therapeutics Market, Europe, Forecasts for Diseased Population, 2008-2015
    • Table 172: CNS Therapeutics Market, Europe, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table173: CNS Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 174: CNS Therapeutics Market, Europe, Historical Figures for Diagnosis Population, 2000-2008
    • Table 175: CNS Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2008-2015
    • Table 176: CNS Therapeutics Market, Europe, Historical Figures for Prescription Population, 2000-2008
    • Table 177: CNS Therapeutics Market, Europe, Forecasts for Prescription Population, 2008-2015
    • Table 178: CNS Therapeutics Market, Europe, Historical Figures for Therapeutic Usage Patterns, 2000-2008
    • Table 179: CNS Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 180: CNS Therapeutics Market, Japan, Historical Revenues ($m), 2000-2008
    • Table 181:CNS Therapeutics Market, Japan, Revenue Forecasts ($m), 2008-2015
    • Table 182: CNS Therapeutics Market, Japan, Historical Figures for Average Cost of Therapy ($), 2000-2008
    • Table 183: CNS Therapeutics Market, Japan, Forecasts for Average Cost of Therapy ($), 2008-2015
    • Table 184: CNS Therapeutics Market, Japan, Historical Figures for Volume, 2000-2008
    • Table 185: CNS Therapeutics Market, Japan, Forecasts for Volume, 2008-2015
    • Table 186: CNS Therapeutics Market, Japan, Historical Figures for Diseased Population,2000-2008
    • Table 187: CNS Therapeutics Market, Japan, Forecasts for Diseased Population, 2008-2015
    • Table 188: CNS Therapeutics Market, Japan, Historical Figures for Treatment Seeking Population, 2000-2008
    • Table 189: CNS Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2008-2015
    • Table 190: CNS Therapeutics Market, Japan, Historical Figures for Diagnosis Population,2000-2008
    • Table 191: CNS Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2008-2015
    • Table 192: CNS Therapeutics Market, Japan, Historical Figures for Prescription Population, 2000-2008
    • Table 193: CNS Therapeutics Market, Japan, Forecasts for Prescription Population, 2008-2015
    • Table 194: CNS Therapeutics Market, Japan, Historical Figures for Therapeutic Usage Patterns, 2000-2008
    • Table 195: CNS Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2008-2015
    • Table 196: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008
    • Table 197: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in Phase I Stage, 2008
    • Table 198: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stage, 2008
    • Table 199: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stage, 2008
    • Table 200: CNS Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008
  • 1.2 List of Figures
    • Figure 1: CNS Therapeutics Market, Global, Market Overview, 2008
    • Figure 2: CNS Therapeutics Market, Global, Key Geographical Trends, 2008
    • Figure 3: CNS Therapeutics Market, Global, Revenue Forecasts ($bn), 2000-2015
    • Figure 4: CNS Therapeutics Market, Global, Revenue Split ($bn), 2000-2015
    • Figure 5: CNS Therapeutics Market, Global, Market Share of Major Disease Sectors, 2008
    • Figure 6: Global CNS Therapeutics Market, Average Cost of Therapy ($), 2000-2015
    • Figure 7: CNS Therapeutics Market, Global, Forecasts for Volume, 2000-2015
    • Figure 8: CNS Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
    • Figure 9: CNS Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
    • Figure 10: CNS Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
    • Figure 11: CNS Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015
    • Figure 12: CNS Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
    • Figure 13: CNS Therapeutics Market, Global, Geographical Distribution of Revenues ($bn), 2000-2015
    • Figure 14: CNS Therapeutics Market, Global, Geographical Comparison of Market Competition, 2008
    • Figure 15: CNS Therapeutics Market, Global, Market Indicators, 2008
    • Figure 16: CNS Therapeutics Market, Global, Analysis of Unmet Needs for Major Disease Sectors, 2008
    • Figure 17: CNS Therapeutics Market, Global, Key Market Events, 2008-2015
    • Figure 18: Alzheimer's Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2000-2015
    • Figure 19: Alzheimer's Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015
    • Figure 20: Alzheimer's Disease Therapeutics Market, Global, Global,Forecasts for Volume, 2000-2015
    • Figure 21: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
    • Figure 22: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
    • Figure 23: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
    • Figure 24: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015
    • Figure 25: Alzheimer's Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
    • Figure 26: Alzheimer's Disease Therapeutics Market, Global, Market Share of Major Therapeutic